Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2022 | 3 |
2023 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
EBioMedicine. 2023 Jan;87:104402. doi: 10.1016/j.ebiom.2022.104402. Epub 2022 Dec 19.
EBioMedicine. 2023.
PMID: 36543718
Free PMC article.
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
Priddy FH, Williams M, Carson S, Lavender B, Mathieson J, Frampton C, Moreland NJ, McGregor R, Williams G, Brewerton M, Gell K, Ussher J, Le Gros G.
Priddy FH, et al.
Vaccine. 2022 Aug 12;40(34):5050-5059. doi: 10.1016/j.vaccine.2022.07.009. Epub 2022 Jul 12.
Vaccine. 2022.
PMID: 35868948
Free PMC article.
Item in Clipboard
Whole genome comparison of a large collection of mycobacteriophages reveals a continuum of phage genetic diversity.
Pope WH, Bowman CA, Russell DA, Jacobs-Sera D, Asai DJ, Cresawn SG, Jacobs WR, Hendrix RW, Lawrence JG, Hatfull GF; Science Education Alliance Phage Hunters Advancing Genomics and Evolutionary Science; Phage Hunters Integrating Research and Education; Mycobacterial Genetics Course.
Pope WH, et al.
Elife. 2015 Apr 28;4:e06416. doi: 10.7554/eLife.06416.
Elife. 2015.
PMID: 25919952
Free PMC article.
Item in Clipboard
Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B, Hooker C, Frampton C, Williams M, Carson S, Paterson A, McGregor R, Moreland NJ, Gell K, Priddy FH, Wiig K, Le Gros G, Ussher JE, Brewerton M.
Lavender B, et al.
Vaccine. 2023 Aug 31;41(38):5535-5544. doi: 10.1016/j.vaccine.2023.07.051. Epub 2023 Jul 27.
Vaccine. 2023.
PMID: 37516574
Free article.
Item in Clipboard
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study.
Lin S, et al.
Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z.
Nat Commun. 2022.
PMID: 35296643
Free PMC article.
Item in Clipboard
Cite
Cite